<DOC>
	<DOC>NCT01238978</DOC>
	<brief_summary>The study will assess the incidence of Hypoglycemia: Percent of patients presenting no hypoglycemia (confirmed events with SMBG and severe episodes) over 6 months follow up in T2DM patients treated with a DPP-4 inhibitor or another OAD as add-on therapy to metformin</brief_summary>
	<brief_title>Phase 4 Study in the Elderly Patients With T2DM</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>Type 2 Diabetes Mellitus (DM) patients aged 65 to 80 years, willing to perform SMBG in case of symptomatic hypoglycemia. HbA1c: 6.5 to 8.5 % with max tolerated dose of metformin monotherapy for at least 3 months. Age &gt; 80 yrs BMI &lt; 22 and â‰¥ 45 kg/m2 Secondary T2 DM Hepatic failure, moderate/severe renal failure (Cl &lt; 50 ml/min) and CHF III &amp; IV ASAT / ALAT &gt; 3 ULN, creatinine clearance &lt; 50 ml/min Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Diabetes mellitus, vildagliptin, hypoglycemia, elderly</keyword>
</DOC>